Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Crispr Therapeutics AG

Healthcare US CRSP

57.35USD
-1.65(2.80%)

Last update at 2025-07-11T16:57:00Z

Day Range

56.9359.48
LowHigh

52 Week Range

36.5291.10
LowHigh

Fundamentals

  • Previous Close 59.00
  • Market Cap3459.38M
  • Volume1389661
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-313.07802M
  • Revenue TTM202.83M
  • Revenue Per Share TTM2.45
  • Gross Profit TTM -261.06301M
  • Diluted EPS TTM-2.79

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -650.50000M 379.53M -348.05600M 67.31M -164.42800M
Minority interest - - - - -
Net income -650.17500M 377.66M -348.86500M 66.86M -164.98100M
Selling general administrative 102.46M 102.80M 88.21M 63.49M 48.29M
Selling and marketing expenses - - - - -
Gross profit -109.81400M 913.08M 0.54M 289.59M 3.12M
Reconciled depreciation 24.17M 17.95M 9.18M 4.72M 3.52M
Ebit -697.33300M 355.57M -354.43500M 42.02M -162.46200M
Ebitda -673.16100M 373.53M -345.25100M 46.74M -158.94300M
Depreciation and amortization 24.17M 17.95M 9.18M 4.72M 3.52M
Non operating income net other 22.66M 6.00M 6.38M 20.57M -5.48500M
Operating income -673.16100M 373.53M -354.43500M 46.74M -158.94300M
Other operating expenses 673.60M 539.55M 354.98M 242.85M 162.07M
Interest expense -46.83300M 23.96M 6.38M 25.29M 0.00000M
Tax provision -0.32500M 1.87M 0.81M 0.45M 0.55M
Interest income - - - 5.47M 4.28M
Net interest income - - - - 0.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.32500M 1.87M 0.81M 0.45M 0.55M
Total revenue 0.44M 913.08M 0.54M 289.59M 3.12M
Total operating expenses 563.35M 539.55M 354.98M 242.85M 162.07M
Cost of revenue 110.25M - - 179.36M 113.77M
Total other income expense net 22.66M 6.00M 6.38M 20.57M -5.48500M
Discontinued operations - - - - -
Net income from continuing ops -650.17500M 377.66M -348.86500M 66.86M -164.98100M
Net income applicable to common shares -650.17500M 377.66M -348.86500M 66.86M -164.98100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2229.57M 2243.06M 2751.88M 1827.97M 1066.75M
Intangible assets 0.02M 0.07M 0.12M 0.18M 0.23M
Earning assets - - - - -
Other current assets 14.39M 37.71M 38.08M 26.14M 43.68M
Total liab 346.77M 367.58M 352.42M 163.73M 127.33M
Total stockholder equity 1882.80M 1875.48M 2399.46M 1664.23M 939.42M
Deferred long term liab - - - - -
Other current liab 50.91M 65.51M 91.90M 71.46M 41.71M
Common stock 2.50M 2.44M 2.39M 2.28M 1.85M
Capital stock 2.50M 2.44M 2.39M 2.28M 1.85M
Retained earnings -999.70000M -846.09000M -195.91500M -573.57600M -224.71100M
Other liab - 18.29M 19.66M 19.41M 26.17M
Good will - - - - -
Other assets - 16.27M 22.20M 18.14M 6.14M
Cash 389.48M 211.88M 923.03M 1168.62M 943.77M
Cash and equivalents - - - - -
Total current liabilities 108.79M 121.11M 119.88M 94.26M 57.11M
Current deferred revenue 4.11M 12.32M 1.01M 2.34M 0.96M
Net debt -150.84500M 32.14M -698.00100M -1107.19100M -891.23200M
Short term debt 15.62M 15.84M 12.16M 11.36M 8.49M
Short long term debt - - - - -
Short long term debt total 238.63M 244.02M 225.03M 61.43M 52.54M
Other stockholder equity 2878.09M 2734.78M 2598.05M 2235.62M 1162.28M
Property plant equipment - 163.63M 137.57M 42.16M 72.83M
Total current assets 1908.08M 1853.03M 2417.51M 1716.62M 987.55M
Long term investments 1.97M 53.13M - - -
Net tangible assets - 1875.48M 2399.46M 1664.05M 939.19M
Short term investments 1304.21M 1603.43M 1456.10M 521.71M -
Net receivables 200.00M 4.64M 0.30M 0.14M 0.10M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 38.15M 27.43M 14.82M 9.09M 5.94M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.91M -15.64700M -5.06700M -0.08300M 0.00700M
Additional paid in capital - - - - -
Common stock total equity - 2.44M 2.39M 2.28M 1.85M
Preferred stock total equity - - - - -
Retained earnings total equity - -846.09000M -195.91500M -573.57600M -224.71100M
Treasury stock - -0.06300M -0.06300M -0.06300M -0.06300M
Accumulated amortization - - - - -
Non currrent assets other 13.57M 16.27M 22.20M 18.14M 6.14M
Deferred long term asset charges - - - - -
Non current assets total 321.49M 390.03M 334.36M 111.35M 79.20M
Capital lease obligations 238.63M 244.02M 225.03M 61.43M 52.54M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -258.65500M -953.72500M -522.81200M 1.32M -2.77300M
Change to liabilities 3.64M 32.21M 15.24M 30.01M 12.36M
Total cashflows from investing activities -258.65500M -1035.43000M -541.17000M 1.32M -2.77300M
Net borrowings - - - - -
Total cash from financing activities 38.59M 250.94M 1016.15M 430.98M 315.93M
Change to operating activities 15.39M -9.71100M 6.36M -8.29800M -3.80200M
Net income -650.17500M 377.66M -348.86500M 66.86M -164.98100M
Change in cash -715.88400M -245.52400M 236.66M 489.00M 216.90M
Begin period cash flow 939.94M 1185.47M 948.81M 459.81M 242.91M
End period cash flow 224.06M 939.94M 1185.47M 948.81M 459.81M
Total cash from operating activities -495.74100M 538.97M -238.36600M 56.68M -96.23900M
Issuance of capital stock 0.97M 213.27M 982.29M 415.02M 307.05M
Depreciation 24.17M 17.95M 9.18M 4.72M 3.52M
Other cashflows from investing activities - - - 8.01M -
Dividends paid - - - - -
Change to inventory - -37.51400M -25.74700M -5.02500M 332.30M
Change to account receivables 0.30M -0.16100M -0.04500M -0.01100M 2.54M
Sale purchase of stock 38.59M 250.94M 1016.15M 430.98M -0.05700M
Other cashflows from financing activities 37.62M 37.68M 33.86M 15.96M 8.94M
Change to netincome 110.42M 102.39M 67.88M 49.52M 34.82M
Capital expenditures 37.19M 81.70M 18.36M 6.68M 2.77M
Change receivables 0.30M -0.16100M -0.04500M -0.01100M 2.54M
Cash flows other operating 15.90M -5.18900M 18.25M -94.42700M 15.51M
Exchange rate changes - - - - -
Cash and cash equivalents changes -715.80400M -245.51300M 236.62M 488.99M 216.92M
Change in working capital 19.84M 26.86M 33.44M -48.43000M 10.55M
Stock based compensation 97.95M 102.39M 66.02M 44.06M 34.98M
Other non cash items 12.47M 14.11M 1.86M -10.53300M 15.41M
Free cash flow -532.92900M 457.27M -256.72400M 49.99M -99.01200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRSP
Crispr Therapeutics AG		 -1.65 2.80% 57.35 - 23.36 17.06 1.78 8.76 14.16
NVO
Novo Nordisk A/S		 -2.2 3.10% 68.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.49 0.70% 70.49 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -8.65 1.80% 470.88 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 4.50 0.80% 564.26 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Crispr Therapeutics AG

Baarerstrasse 14, Zug, Switzerland, 6300

Key Executives

Name Title Year Born
Dr. Samarth Kulkarni Ph.D. CEO & Director 1979
Mr. Brendan Smith M.B.A. Sr. VP, CFO & Principal Accounting Officer 1976
Dr. Lawrence Otto Klein Ph.D. Chief Operating Officer 1982
Mr. James R. Kasinger Gen. Counsel & Sec. 1972
Dr. Rodger Novak M.D. Founder, Chairman & Pres 1967
Mr. Shaun Foy Founder NA
Dr. Emmanuelle Marie Charpentier Co-Founder & Scientific Advisory Board Member NA
Dr. Craig C. Mello Ph.D. Scientific Founder & Advisory Board Member NA
Dr. Chad A. Cowan Ph.D. Scientific Founder NA
Dr. Matthew Porteus M.D., Ph.D. Scientific Founder & Advisory Board Member 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.